1. Home
  2. DMB vs RCEL Comparison

DMB vs RCEL Comparison

Compare DMB & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BNY Mellon Municipal Bond Infrastructure Fund Inc.

DMB

BNY Mellon Municipal Bond Infrastructure Fund Inc.

HOLD

Current Price

$10.76

Market Cap

200.1M

Sector

Finance

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$4.22

Market Cap

171.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMB
RCEL
Founded
2013
N/A
Country
United States
United States
Employees
N/A
226
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
200.1M
171.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DMB
RCEL
Price
$10.76
$4.22
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$7.88
AVG Volume (30 Days)
44.5K
225.5K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
4.17%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$17.17
Revenue Next Year
N/A
$49.82
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.85
$3.22
52 Week High
$11.28
$7.12

Technical Indicators

Market Signals
Indicator
DMB
RCEL
Relative Strength Index (RSI) 41.46 46.61
Support Level $10.72 $4.09
Resistance Level $10.93 $4.57
Average True Range (ATR) 0.14 0.34
MACD -0.02 -0.00
Stochastic Oscillator 8.39 14.87

Price Performance

Historical Comparison
DMB
RCEL

About DMB BNY Mellon Municipal Bond Infrastructure Fund Inc.

BNY Mellon Municipal Bond Infrastructure Fund, Inc. is a diversified closed-end management investment company. The fund's investment objective is to provide as high a current income exempt from regular federal income tax as is consistent with the preservation of capital. It invests in transportation, energy and utilities, social infrastructure, and water and environmental sectors.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: